Theratechnologies (NASDAQ:THTX) Releases Earnings Results, Misses Estimates By $0.03 EPS

Theratechnologies (NASDAQ:THTX) released its earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03), Fidelity Earnings reports. Theratechnologies had a negative net margin of 37.10% and a negative return on equity of 112.84%. During the same quarter in the previous year, the firm posted ($0.09) EPS.

Theratechnologies stock opened at $3.57 on Thursday. The company’s 50-day moving average price is $3.61 and its 200-day moving average price is $3.63. Theratechnologies has a twelve month low of $1.83 and a twelve month high of $4.46. The company has a quick ratio of 1.74, a current ratio of 2.41 and a debt-to-equity ratio of 1.52. The company has a market cap of $338.13 million, a PE ratio of -11.90 and a beta of 1.65.

Several analysts have commented on THTX shares. Canaccord Genuity cut shares of Theratechnologies from a “buy” rating to a “hold” rating and decreased their price target for the stock from $8.00 to $3.00 in a research note on Thursday, July 29th. Zacks Investment Research upgraded shares of Theratechnologies from a “sell” rating to a “hold” rating in a research note on Wednesday, September 15th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from, the stock has a consensus rating of “Hold” and a consensus target price of $3.17.

A hedge fund recently raised its stake in Theratechnologies stock. Morgan Stanley lifted its holdings in Theratechnologies Inc. (NASDAQ:THTX) by 143.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,716,512 shares of the company’s stock after buying an additional 1,012,777 shares during the period. Morgan Stanley owned about 1.81% of Theratechnologies worth $6,660,000 at the end of the most recent reporting period. Institutional investors own 19.29% of the company’s stock.

About Theratechnologies

Theratechnologies, Inc is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Featured Story: Most Volatile Stocks

Earnings History for Theratechnologies (NASDAQ:THTX)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.